Center for Health Outcomes Research, United BioSource Corporation, London, UK.
Patient. 2009 Sep 1;2(3):151-7. doi: 10.2165/11314870-000000000-00000.
: Chronic urticaria (hives) affects a sizeable number of people worldwide, perhaps as much as 3%. It is often accompanied by angioedema. The negative effects of urticaria and angioedema, and any adverse effects of treatment, can result in significant patient burden.
: To explore patients' use of, preferences for, and willingness to switch from prescription to over-the-counter (OTC) treatments for chronic urticaria. In addition, we compared treatment satisfaction with the treatment used most recently for their chronic urticaria.
: Data were collected by an online survey using members of international consumer survey panels representative of the general populations in France and Germany. Panelists with urticaria were selected based on answers to screening questions. Respondents were asked, in their native language, questions about their typical course of treatment (prescription vs OTC), satisfaction with treatment, troublesomeness of their typical outbreak, whether their condition had improved or become worse over the past 12 months, and their willingness to try a new treatment if one became available. Descriptive analyses were performed on selected variables. Groups were compared using difference of means tests. Correlations and multiple regressions were performed to assess predictors of satisfaction with treatment and likelihood of switching treatment.
: The final study sample consisted of 405 patients. Patients who used prescription treatments were more satisfied and reported greater treatment benefits with their treatment than those using OTC treatments. Patients who felt that their condition had become worse over the past 12 months were more likely to consider switching treatments. Respondents who used Aerius (desloratadine) most recently for treating their symptoms reported greater satisfaction with treatment than did those who used other commonly used prescription treatments most recently.
: These results suggest that prescription treatments for chronic urticaria have a valuable place amongst the treatments offered for this very uncomfortable condition. Moreover, patients expressed preference for prescription treatments in large part because they felt that these treatments work.
慢性荨麻疹(荨麻疹)影响了全球相当数量的人群,其发病率可能高达 3%。它常伴有血管性水肿。荨麻疹和血管性水肿的负面影响,以及治疗的任何不良反应,都会给患者带来巨大的负担。
探索患者对慢性荨麻疹处方药与非处方药(OTC)治疗的使用、偏好和转换意愿。此外,我们比较了患者对最近用于治疗慢性荨麻疹的治疗方案的满意度。
通过一项在线调查收集数据,该调查使用了代表法国和德国普通人群的国际消费者调查小组的成员。根据筛选问题的答案,选择有荨麻疹的小组参与者。调查对象以母语回答了关于他们的典型治疗方案(处方药与 OTC)、对治疗的满意度、典型发作的麻烦程度、过去 12 个月病情是否改善或恶化,以及如果有新的治疗方案可供选择是否愿意尝试的问题。对选定的变量进行描述性分析。使用均值差异检验比较组间差异。进行相关性和多元回归分析,以评估治疗满意度和转换治疗可能性的预测因素。
最终的研究样本包括 405 名患者。使用处方药治疗的患者对治疗的满意度更高,报告的治疗益处更大,而使用 OTC 治疗的患者则不然。过去 12 个月感觉病情恶化的患者更有可能考虑转换治疗方案。最近使用 Aerius(地氯雷他定)治疗症状的患者报告的治疗满意度高于最近使用其他常用处方药治疗的患者。
这些结果表明,慢性荨麻疹的处方药在治疗这种非常不适的疾病的方案中具有重要地位。此外,患者表示偏爱处方药,在很大程度上是因为他们认为这些治疗方法有效。